Epidemiology, risk factors and prognosis of ventilator-associated pneumonia during severe COVID-19: Multicenter observational study across 149 European Intensive Care Units
Authors' conclusion
VAP affected almost half of mechanically ventilated COVID-19 patients.
Study context
- Population
- COVID-19 patients invasively ventilated for at least 48 h, prospective multicentre COVID-ICU databaseanalysed
- Participants
- 3,388 participants
- Exposure
- Ventilator-associated pneumonia (VAP) vs no VAP
- VAPn = 1,523
- Outcome
- VAP incidence
Methodological detailsprospective database, cause-specific Cox regression, multivariable Cox regression
- Prospective database
- Cause-specific Cox regression
- Multivariable Cox regression
Main finding
As reported in the abstract
VAP
45.5%
1523
- Risk factor: male gender
- HR 1.26 (95% CI 1.09-1.46)
- Risk factor: concomitant bacterial pneumonia at ICU admission (HR, 1.10-1.67)
- 1.36
- PaO2/FiO2 at intubation, per 10 mmHg increase (HR, 0.98-0.99)
- 0.99
- NMBA (HR, 0.76-0.998)
- 0.89
- Corticosteroids (HR, 1.09-1.47)
- 1.27
Observational data: associations, not effects.
Further findings
| Outcome | HR (CI) | |
|---|---|---|
| 90-day mortality | 1.34 (1.16–1.55) | |
| 90-day mortality, late VAP · 90 daysLate VAP vs No VAP | 1.51 (1.26–1.81) | |
| 0.512Hazard ratio (log scale) |
Mortality, Pseudomonas-related vs non-Pseudomonas-related VAP
- Similar impact on mortality
Identified bacteria
- Mainly Enterobacteriaceae, then Staphylococcus aureus and Pseudomonas aeruginosa
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Epidemiology, risk factors and prognosis of ventilator-associated pneumonia during severe COVID-19: Multicenter observational study across 149 European Intensive Care Units. Anaesth Crit Care Pain Med. Published 9 December 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →